For Immediate Release
Chicago, IL – July 28, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Facebook FB, Verizon Communications VZ, Pfizer PFE, Novartis NVS and Philip Morris International PM.
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Facebook, Verizon and Pfizer
The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Facebook, Verizon Communications and Pfizer. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Facebook shares have been essentially flat over the last few weeks, likely reflecting unfavorable headlines related to advertizer boycotts. But the stock has outperformed the S&P 500 over the past year (+18.9% vs. +6.9%) and the Zacks analyst expects the stock to move higher following strong numbers in its quarterly release after the market’s close on Wednesday, July 29th.
Driving this optimism is the view that the company should continue to benefit from growth in Instagram Stories and Feed, and an expanding user base in Asia Pacific.
The company helped people connect during the coronavirus pandemic. Notably, voice and video calling more than doubled on Messenger and WhatsApp. The launch of Messenger Rooms for video call, which can accommodate 50 people, and WhatsApp video support for up to eight users are noteworthy in this regard.
However, Facebook expects ad-sales to be hurt by weakness in travel and automotive industries. Further, a number of companies have announced plans to freeze ad spending on Facebook due to its failure to eradicate hate speech and misinformation. This is expected to hurt top-line growth, at least in the near term. Higher operating expense is also expected to dent the operating margin in 2020.
Shares of Verizon have modestly lagged the Zacks Wireless industry this year (-6.9% vs. -5.7%), but the Zacks analyst is optimistic about this wireless operator on the back of a disciplined network strategy, including accelerated 5G deployment despite economic uncertainties stemming from the COVID-19 crisis.
It launched the 35th 5G Ultra Wideband city in San Diego and intends to make 60 5G mobility cities this year. It is building the 5G home solution and mobile edge computing on the same network. Verizon expects to see strong momentum heading into the second half of 2020.
However, it is facing headwinds in the media business due to sluggish advertising trends. The company operates in a fiercely-competitive U.S. wireless market. Also, Verizon is spending heavily on promotion and lucrative discounts to attract customers, which erodes profitability.
Pfizer shares have lost -1.2% over the past six months against the Zacks Large-Cap Pharmaceuticals industry’s rise of +0.5%. The Zacks analyst believes that the Consumer Healthcare joint venture with Glaxo, the Array acquisition and the pending merger of Upjohn unit with Mylan, if successful, will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
The smaller Pfizer should see better revenue growth as the Lyrica LOE cliff will go away. Pfizer expects continued strong growth of key brands like Ibrance, Inlyta and Eliquis to drive sales in 2020. However, Pfizer expects a significant impact from coronavirus-related business disruption in Q2, which it expects to ease in the second half.
Meanwhile, currency headwinds and pricing pressure are other top-line headwinds. Estimates have gone up ahead of Q2 earnings. Pfizer has a mixed record of earnings surprises in the recent quarters.
Other noteworthy reports we are featuring today include Novartis and Philip Morris International.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year’s 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Zacks Investment Research